Sunday, September 24, 2017
The biopharma industry’s continuing focus on productivity and efficiency is driving manufacturers to focus on core competencies and to consider outsourcing activities that can be handled more effectively by CMOs.
Friday, September 30, 2016
Around 45% of biopharmaceutical manufacturing organizations expect to off-shore at least some of their operations over the next five years, with the figure dependent on the nature of the activity, according to BioPlan Associates’ 13th Annual Report ...
Vendors to the biopharmaceutical manufacturing industry are seeing an
opportunity to offer valuable services that complement their products.
This is increasingly a strategic priority for introducing new products,
according to BioPlan Associates’ ...
Contract manufacturing organizations (CMOs) are typically on the
leading edge of new biopharmaceutical manufacturing technology
adoption, as evidenced by many CMOs hiring for positions like
‘technology scout’ and ‘director of innovation’. CMOs ...
The biopharmaceutical manufacturing community
continues to find it difficult to staff key
positions, and is turning instead to outsourcing
to fill the gaps. According to preliminary
results from BioPlan Associates’ 13th Annual
Report and Survey ...
Thursday, February 05, 2015
Although relatively few biosimilar products have entered major markets, including no approvals yet in the US, this new class of biopharmaceuticals
is already having a major impact on many (bio)pharmaceutical contract manufacturing organizations (...
Tuesday, January 28, 2014
Outsourcing of non-core activities continues to be a value-driven calculus, as the biopharmaceutical manufacturing industry remains very much focused on productivity gains. However,
there are signs that the outsourcing landscape has moved beyond its...
Wednesday, August 07, 2013
The embracement of single-use applications by the biopharmaceutical
industry is no secret. They now dominate clinical scale manufacturing,
and as the pipeline of new products advances, are now moving into
mainstream commercial bioproduction. ...
Monday, September 17, 2012
China continues its remarkable advance last year as the most likely outsourcing destination, edging out stalwarts U.S. and Germany. In our 9th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production, research analysis from...
The biomanufacturing industry continues to have problems with downstream operations, as evidenced by the 7 in 10 (71.9%) respondents to our 9th Annual Report and Survey of Biopharmaceutical Manufacturing who report this year that they are seeing at ...